ACMR Up 140% On Key Wins, But Valuation Models Disagree

Edgen Stock

·Dec 17 2025, 11:59

Share to

Share to

Copy link

Key Takeaways

ACM Research has achieved significant operational milestones, including delivering a key system and getting tools tested by Intel, driving its stock up over 140% in a year. However, valuation models present a conflicting picture, with narrative analysis suggesting it's undervalued while a discounted cash flow model indicates it may be overvalued.

Operational Milestones: The company delivered its first Ultra Lith Baker system and had its chipmaking tools validated by Intel, signaling strong technical progress.
Strong Shareholder Returns: ACMR stock has returned over 300% in the last three years and is up more than 140% in the past year alone.
Conflicting Valuations: While one analysis pegs fair value at $40.81, suggesting a 7.6% upside from its $37.73 price, a discounted cash flow model implies a fair value of only $30.14.

ACMR Stock Gains 140% on Intel Validation and System Delivery

ACM Research (ACMR) secured two major operational wins, delivering its first Ultra Lith Baker system for high-volume manufacturing and seeing its chipmaking tools tested within Intel's advanced process lines. These successes have powered significant investor returns, with the stock price climbing approximately 20% in the last month and more than 140% over the past year. The long-term performance is even more powerful, with a three-year total shareholder return exceeding 300%, indicating sustained positive momentum.

Valuation Models Clash on Future Growth

Despite the strong performance, valuation analyses present a divided outlook for the stock. A narrative-based model places ACMR's fair value at $40.81, suggesting it remains 7.6% undervalued from its last closing price of $37.73 on December 16. This view is supported by the company's major investments in new manufacturing and R&D capacity in Lingang, China, and Oregon, alongside a strategic inventory buildup to counter geopolitical risks. However, a discounted cash flow (DCF) model paints a more cautious picture, estimating a fair value of just $30.14. This suggests the current market price may have already factored in excessive optimism regarding future growth and margin resilience, potentially leaving the stock overvalued based on its cash flow fundamentals.